Experience with basiliximab in pediatric liver graft recipients

Ganschow, Rainer; Lyons, M.; Grabhorn, Enke; Venzke, A.; Broering, DC; Rogiers, Xavier; Hellwege, H. H.; Burdelski, M.

doi:10.1016/s0041-1345(01)02551-9

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the current study is the first to show that the addition of basiliximab to a standard tacrolimus-based immunosuppressive regimen is effective and well tolerated in adults undergoing OLTx. The effects of basiliximab on ACR and patient survival in OLTx have been more extensively studied in standard cyclosporine-based regimens (22)(23)(24)(25). In a phase III study involving 381 orthotopic liver transplant recipients, the addition of basiliximab to cyclosporine-and steroid-based immunosuppression reduced the overall rate of biopsy-confirmed ACR at 6 months from 43.5% to 35.1%.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Basiliximab with a Tacrolimus-Based Regimen in Liver Transplant Recipients

et al. 2004

View full text Add to dashboard Cite

Background. Induction with monoclonal antibodies for prevention of acute cellular rejection (ACR) may avoid many of the adverse events associated with polyclonal antibodies. Basiliximab, a chimeric monoclonal antibody directed against the ␣-chain of the interleukin 2 receptor (CD25), has been extensively evaluated as an induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen. In this study, we assessed the efficacy and safety of basiliximab in combination with a tacrolimus-based regimen after liver transplantation. Methods. Fifty consecutive liver transplants (47 cadaveric donors; 3 living donors) were analyzed. All patients received two 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/day; 10 -15 ng/mL target trough levels) and a tapered dose regimen of steroids. Follow-up ranged from 404 to 1,364 days after transplantation (mean 799.89 days, SDϮ257.37; median 796 days). Results. A total of 88% of patients remained rejection-free during follow-up with an actuarial rejection-free probability of 75% within 3 months. The actuarial patient survival rate at 3 years was 88%, and the graft survival rate was 75%. Twelve (24%) patients experienced one episode of sepsis, requiring temporary reduction of immunosuppressive therapy. There were no immediate side effects associated with basiliximab and no evidence of cytomegalovirus infection or posttransplant lymphoproliferative disorder. Conclusions. Basiliximab in combination with a tacrolimus-based immunosuppressive regimen is effective in reducing episodes of ACR and increasing ACR-free survival after liver transplantation. In addition, basiliximab does not increase the incidence of adverse effects or infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Basiliximab with a Tacrolimus-Based Regimen in Liver Transplant Recipients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Longer‐term use may include their incorporation into safe CNI sparing regimens in liver graft recipients with emerging nephrotoxicity or neurotoxicity and into steroid avoidance or minimization regimens. The significant reduction in acute rejection rates with BAS mentioned above in pediatric LT (141,142) needs to be confirmed in large, multicenter prospective studies.…”

Section: Corticosteroidsmentioning

confidence: 99%

“…Rates of rejection-free graft survival were also significantly higher (75% versus 50%). Ganschow et al (142) treated prospectively 54 pediatric liver recipients with BAS (either 10 or 20 mg, depending on their weight) in two single doses at 6 hours postgraft reperfusion and on day 4 posttransplant. All children received CSA and corticosteroid.…”

Section: Clinical Efficacymentioning

confidence: 99%